1521-009X/49/11/995–1002$35.00
DRUG METABOLISM AND DISPOSITION

https://doi.org/10.1124/dmd.121.000601
Drug Metab Dispos 49:995–1002, November 2021

Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450 [S]

Sheri Smith, Michael Lyman, Bennett Ma, Donald Tweedie, and Karsten Menzel

Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey

Received June 30, 2021; Accepted August 10, 2021

ABSTRACT

Recognizing the challenges of determining the relative contribution of different drug metabolizing enzymes to the metabolism of slowly metabolized compounds, a cytochrome P450 reaction phenotyping (CRP) method using cocultured human hepatocytes (HEPATOPAC) has been established. In this study, the emphasis on the relative contribution of different cytochrome P450 (P450) isoforms was assessed by persistently inhibiting P450 isoforms over 7 days with human HEPATOPAC. P450 isoform-selective inhibition was achieved with the chemical inhibitors furafylline (CYP1A2), tienilic acid (CYP2C9), (+)-*N*-3-benzylnirvanol (CYP2C19), paroxetine (CYP2D6), azamulin (CYP3A), and a combination of 1-aminobenzotriazole and tienilic acid (broad spectrum inhibition of P450s). We executed this CRP method using HEPATOPAC by optimizing for the choice of P450 inhibitors, their selectivity, and the temporal effect of inhibitor concentrations on maintaining selectivity of inhibition. In general, the established CRP method using potent and selective chemical inhibitors allows to measure the relative contribution of P450s and to calculate the fraction of metabolism (f_m) of low-turnover compounds. Several low-turnover compounds were used to validate this CRP method by determining their hepatic intrinsic clearance and f_m, with comparison with literature values. We established the foundation of a robust CRP for low-turnover compound test system which can be expanded to include inhibition of other drug metabolizing enzymes. This generic CRP assay, using human long-term hepatocyte cultures, will be an essential tool in drug development for new chemical entities in the quantitative assessment of the risk as a victim of drug-drug interactions.

SIGNIFICANCE STATEMENT

An ongoing trend is to develop drug candidates which have limited metabolic clearance. The current studies report a generic approach to conducting reaction phenotyping studies with human HEPATOPAC, focusing on P450 metabolism of low-turnover compounds. Potent and selective chemical inhibitors were used to assess the relative contribution of the major human P450s. Validation was achieved by confirming hepatic intrinsic clearance and fraction of metabolism for previously reported low-turnover compounds. This approach is adaptable for assessment of all drug metabolizing enzymes.

Introduction

When determining the potential for drug-drug interactions (DDI) of a new chemical entity (NCE), it is important to elucidate both the perpetrator profile of drugs on transporters and metabolizing enzymes, i.e., drugs as inhibitors, inactivators and/or inducers of these proteins and also understand the mechanisms by which drugs are eliminated in humans (victim profile). The potential victim DDI risk in the clinic is predicted from in vitro assays early in drug discovery by identifying the routes of metabolism and transporter-mediated disposition of NCEs (Zientek and Youdim, 2015; Di, 2017). There is a focus on understanding the cytochrome P450 (P450)-mediated drug interactions, as many drugs are metabolized by P450s in the liver (Zientek and Youdim, 2015; Cerny, 2016; Di, 2017; Ogilive et al., 2019). Phenotyping is a term which was adopted to define the enzymes responsible for metabolism of a compound (e.g., Fujino et al., 1982). P450 reaction phenotyping (CRP) aims to determine the relative quantitative contribution of P450 isoforms to the metabolism (f_m) of an NCE in vitro. There have been fundamentally four approaches for CRP, namely metabolism by human recombinant P450s, inhibition of metabolism with human liver microsomes (HLM) by isoform-selective chemical inhibitors, inhibition by isoform-selective inhibitory antibodies, and correlation analysis. Recommendations by Pharmaceutical Research and Manufacturers of America (Bjornsson et al., 2003) and regulators, for example US Food and Drug Administration (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions), proposed that two independent studies should be sufficient, which are typically metabolism by recombinant P450 and inhibition of metabolism using isoform-selective chemical inhibitors.

With drug discovery scientists striving to generate drug candidates that are suitable for once daily or less frequent dosing to increase patient adherence and ensure pharmacological coverage (Bleecker et al., 2012;

This work received no external funding.

No author has an actual or perceived conflict of interest with the contents of this article.

dx.doi.org/10.1124/dmd.121.000601.

[S] This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: ABT, 1-aminobenzotriazole; AZM, azamulin; BNZ, (+)-*N*-3-benzylnirvanol; CL_{int}, intrinsic clearance; CRP, P450 reaction phenotyping; DDI, drug-drug interactions; DME, drug metabolizing enzyme; ESI, electrospray ionization; f_m, fraction of metabolism; FUR, furafylline; HLM, human liver microsomes; LC-MS/MS, liquid chromatography-tandem mass spectrometry; NCE, new chemical entity; P450, cytochrome P450; PXT, paroxetine; TA, tienilic acid.

Smith et al., 2018), these NCEs often exhibit low metabolic turnover in liver preparations. Consequently, evaluation of those compounds with the traditional CRP methods is challenging since HLM, recombinant enzymes, and human hepatocyte suspensions gradually lose activity of drug metabolizing enzymes beyond a standard incubation period (Elaut et al., 2006, Stringer et al., 2008). The relay method (Di et al., 2012) and incubation with cocultured hepatocytes (Chan et al., 2013; Lin and Khetani, 2017) have been used to assess hepatic clearance for low-turnover compounds.

Long-term viable cultures of hepatocytes have proved to be valuable in maintenance of enzyme activity for extended periods of time (Khetani and Bhatia, 2008; Chan et al., 2013, Bonn et al., 2016). Furthermore, accurate in vitro to in vivo extrapolation using cocultured human hepatocytes has been observed for low-turnover compounds (Chan et al., 2013; Lin and Khetani, 2017), which should provide an additional layer of confidence in applying these systems to assess f_m.

Our goal was to develop a generic system to conduct CRP studies for low-turnover compounds with confidence. For proof-of-principle, we focused on phenotyping of P450-mediated reactions, since these are the enzymes for which most of the selective inhibitors and substrates have been identified. Initial discussions concentrated on identifying highly efficient P450 selective inactivators as the extent of inhibition would then be defined primarily by the turnover of the P450 protein. However, first-order degradation rate constant (k_{deg}) values have not been reported for all P450s, and reported values can have broad ranges (Yang et al., 2008). As such, we elected to merely identify potent inhibitors and apply a daily routine for inhibition/inactivation. We also recognize that, although inactivation is a potential mechanism for oxidative enzymes, this mechanism cannot be applied to many other drug metabolizing enzymes (DME).

Although chemical inhibitors in HEPATOPAC have been used to ablate specific P450 isoforms (Lin and Khetani, 2017), characterization of selectivity toward different P450 isoforms, as required for CRP analysis, has not been demonstrated. These long-term cultures need to ensure complete inhibition under conditions where the inhibitor may be metabolized and where enzymes are regenerated as part of a normal cell function. Simply applying supersaturated concentrations of inhibitors is not a viable option, as most inhibitors are only selective within a specific range of concentrations (Ogilive et al., 2019). An additional challenge with these studies is the potential for compounds to induce DME during the extended incubation period.

This report describes the development of a specific CRP method using chemical inhibitors with human HEPATOPAC. Potent and selective chemical inhibitors were identified to assess the relative contribution of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, i.e., to calculate the f_m of low-turnover compounds. The established CRP method was validated with low-turnover compounds by determining their hepatic CL_{int} and f_m, with comparison with literature values. In addition, the report will discuss the selection of P450 inhibitors and unique challenges that needed to be overcome through the investigation.

Materials and Methods

Chemicals. Furafylline (FUR), phenacetin, acetaminophen, tizanidine, tienilic acid (TA), diclofenac, 4′-hydroxydiclofenac, tolbutamide, (+)-*N*-3-benzylnirvanol (BNZ), *S*-mephenytoin, 4-hydroxymephenytoin, voriconazole, paroxetine (PXT), dextromethorphan, dextrorphan, risperidone, azamulin (AZM), midazolam, 1′-hydroxymidazolam, disopyramide, 1-aminobenzotriazole (ABT), labetalol, and imipramine were purchased from Sigma-Aldrich (St. Louis, MO), Toronto Research Chemicals (North York, ON, Canada), or Cayman Chemical Company (Ann Arbor, MI). HEPATOPAC maintenance medium and metabolic stability application medium were obtained from BioIVT (Medford, MA). Other reagents were of analytical grade or higher.

HEPATOPAC. HEPATOPAC micropatterned cocultures plates were purchased from BioIVT (Westbury, NY) and were prepared from pooled cryopreserved primary human hepatocyte lots (AMH , ACR and KCB; 10-subject, mixed gender pool for each lot) or from a single-donor lot (VKB ; male). Human hepatocytes were seeded with a density of approximately 20,000 primary hepatocytes per well in a 24-well plate format, with a cell density ratio of 3:1 for hepatocytes and 3T3 murine fibroblasts as specified by the vendor. Fibroblast controls were included for intrinsic clearance experiments. Upon arrival of the human HEPATOPAC plates, shipping media was replaced with human HEPATOPAC maintenance media. Plates were kept in an incubator equilibrated at 37°C under a 10% CO_2 atmosphere and 95% relative humidity for 48 hours prior to an experiment. HEPATOPAC plates were changed to serum-free media 2 hours prior to initiating CRP studies at 37°C with 5% CO_2 atmosphere and 95% relative humidity.

Application of Chemical Inhibitors. The P450-selective chemical inhibitors and their incubation concentrations used were FUR at 1 μM (CYP1A2), TA at 0.015 μM (CYP2C9), BNZ at 0.5 μM (CYP2C19), PXT at 1.8 μM (CYP2D6), AZM at 1 μM (CYP3A), and ABT at 1 mM supplemented with TA at 15 μM (broad spectrum inhibitor of P450s), with conditions optimized in prior experiments. All inhibitors were prepared in 95% ethanol/5% DMSO with the exception of ABT, which was dissolved with sterile water. Each HEPATOPAC well was preincubated with an inhibitor(s) for 24 hours prior to the initiation of the experiment. The final amount of organic solvent was ≤0.1% in HEPATOPAC wells during preincubation. After the preincubation period, the media containing inhibitor(s) was removed, and HEPATOPAC wells were incubated with media containing chemical inhibitor(s) supplemented with a low-turnover probe substrate. An additional aliquot of the chemical inhibitor(s) was added to the incubation daily. One exception to this daily aliquot was CYP2D6 inhibition with PXT. The addition of PXT was optimized and required to be added as a predose and on days 4 and 7, only.

The concentration of the chemical inhibitors was measured for the 7-day incubation period based on daily aliquots applied. The measured concentration increased by 2- to 3-fold for the duration of 7 days. The final amount of organic solvent accumulated between 0.5% to 1% throughout the 7-day incubations for all inhibition conditions based on daily aliquots of chemical inhibitor(s), and no solvent effects were observed upon microscopic evaluation of cell morphology.

P450 Enzyme Activity and Chemical Inhibitor Selectivity Study. Enzyme activities were used to evaluate P450 chemical inhibitor selectivity, conducted by measuring oxidative metabolite formation of P450-selective substrates. After a preincubation period with the chemical inhibitor(s), the media was replaced with fresh media containing inhibitor at pretreatment concentration levels and a cocktail of P450-selective substrates. The substrates used were phenacetin for CYP1A2 at 100 μM final incubation concentration, diclofenac for CYP2C9 at 25 μM, and midazolam for CYP3A at 15 μM. In a separate cocktail, *S*-mephenytoin for CYP2C19 at 150 μM and dextromethorphan for CYP2D6 at 25 μM were combined. The plates were incubated at 37°C with 5% CO_2 atmosphere and 95% relative humidity for 100 minutes (optimized for 24-well HEPATOPAC plates). After 100 minutes, all the collected samples were quenched with one volume of acetonitrile containing 200 nM of internal standards (labetalol, diclofenac, and imipramine) and stored at −70°C until all samples were collected. After all samples were collected, the quench plate was centrifuged at 2900*g* for 10 minutes, and 100 μl supernatant was removed and transferred to clean injection plates (as shown in experimental scheme, Fig. 1). The formation of the corresponding primary oxidative metabolites (acetaminophen, 4'-hydroxydiclofenac, 4-hydroxymephenytoin, dextrorphan, 1'-hydroxymidazolam) was measured by LC-MS/MS analysis to examine the enzyme activity and inhibitor specificity for each isoform on each of the 7 days. Representative P450 activity was calculated and denoted as an average ± S.E. from $n = 4$ to 8 experiments, each obtained from triplicates determinations. Percent activity was calculated for inhibitor specificity for each isoform. The percent activity remaining of the P450s as a function of time was calculated from triplicate determinations for each P450 and was plotted as mean ± S.D. HEPATOPAC incubations without chemical inhibitors were conducted in the same manner as described above with the exclusion of chemical inhibitor(s).

Determining the Intrinsic Clearance of a Test Compound. After a 24-hour pretreatment with specific chemical inhibitor(s), incubation reactions were started by adding 0.5 ml HEPATOPAC metabolic stability medium containing the test compound at a final concentration of 0.3 μM and P450-selective



Fig. 1. Schematic overview of Reaction phenotyping using micropatterned cocultures

chemical inhibitor(s) at concentrations specified in the previous section to each well of the HEPATOPAC plate. P450-selective inhibitors were aliquoted into each well on a daily basis (except for P450 2D6 inhibition, see previous section for details). The incubations were terminated at 0, 24, 48, 72, 96, 120, 144, or 168 hours. Sample work-up and preparation of the LC-MS/MS sample were conducted in the same manner as described in the previous section. HEPATOPAC incubations without chemical inhibitors were conducted in the same manner as described above with the exclusion of chemical inhibitor(s). An additional plate containing stromal cells (mouse embryonic 3T3 fibroblasts) was incubated with the test compound and served as a control. All assays and measurements were performed in triplicate determinations. Parent disappearance versus time profiles of low-turnover substrates were generated for untreated and treated with chemical inhibitor or incubated with stromal cells.

LC-MS/MS Analysis. Samples were analyzed by LC-MS/MS using a Waters Acquity UPLC (Milford, MA) coupled to an AB Sciex 4500 triple quadrupole mass spectrometer (Framingham, MA). Chromatographic separation was obtained using a Waters Xbridge Shield RP18 column (2.1 × 50 mm, 3.5 µm). Solvent A consisted of 0.1% formic acid in water, and solvent B of acetonitrile containing 0.1% formic acid, and were delivered at a constant flow rate of 0.5 ml/min. The solvent gradient initiated at 5% B for 0.5 minutes and then increased linearly to 80% B over 4 minutes. The gradient was further increased to 90% B in 0.1 minutes, held for 0.9 minutes, and then returned to 5% B in 0.1 minutes. The column was re-equilibrated at initial conditions for 0.9 minutes before injection of the next sample. Mass spectrometric analysis was performed with electrospray ionization (ESI) in the positive mode. For quantification, selected reaction monitoring experiments were performed to detect ion pairs at *m/z* 312/231 (4′-hydroxydiclofenac), 235/150 (4-hydroxymephenytoin), 258/157 (dextrorphan), 342/203 (1′-hydroxymidazolam). Internal standards ion pairs at *m/z* 329/162 (labetalol) or 281/193 (imipramine) were used to monitor the instrument performance. The internal standard closest to the retention time of the analyte of interest was used. Internal standards labetalol and imipramine are interchangeable, since both are close to analytes retention time (Supplemental Table 2). Acetaminophen chromatography separation was obtained using a Phenomenex Synergi C18 column (2.1 × 50 mm, 3.5 µm). Solvents A and B were identical to the method mentioned in the beginning of this section and delivered at a constant flow rate of 0.5 ml/min. The solvent gradient initiated at 2% B for 0.4 minutes and then increased linearly to 90% in 0.5 minutes, held for 0.6 minutes, and then returned to 2% in 0.7 minutes. The column was re-equilibrated at initial conditions for 0.93 minutes before injection of the next sample. Mass spectrometric analysis was performed with ESI in the positive mode. For quantification, selected reaction monitoring experiments were performed to detect ion pairs at *m/z* 152/110 (acetaminophen).

Modifications in chromatography conditions were made for several test compounds as needed. Chromatographic separation was achieved using Acquity UPLC BEH Shield RP18 column (2.1 × 50 mm, 1.7 µm). Solvent A consisted of 0.1% formic acid in water, and solvent B of acetonitrile containing 0.1% formic acid, and was delivered at a constant flow rate of 0.75 ml/min. The solvent gradient initiated at 5% B for 0.2 minutes and then increased linearly to 95% in 1.8 minutes, held for 0.7 minutes, and then returned to 5% in 0.7 minutes. The column was re-equilibrated at initial conditions for 0.6 minutes before injection of the next sample. Mass spectrometric analysis was carried out with ESI in the positive mode. For quantification, selected reaction monitoring experiments were performed to detect ion pairs at *m/z* 271/91 (tolbutamide), 340/194 (disopyramide), 350/281 (voriconazole), 411/191 (risperidone), and 254/44 (tizanidine).

Data Analysis and Clearance Calculations. For low-turnover compounds, data showing time-dependent reduction in substrate concentration, as indicated by the peak area ratio, were fitted to the monoexponential decay model (eq.1) using GraphPad Prism 8 (San Diego, CA):

$$C_t = C_0 \times e^{-kt} \quad (1)$$

where k represents the elimination rate constant determined based on the substrate concentration remaining at t = 0 (C_o; 100%) and at time t (C_t). Intrinsic clearance (CL_{int}) values were calculated as seen in Eq. 2:

$$CL_{int} = \frac{k \times SF \times HLW}{P \times fu_{hep}} \quad (2)$$

where SF is the hepatocellularity of 99 million cells/g liver (Barter et al., 2007), HLW is the human liver weight of 25 g liver/kg body weight

(Howgate et al., 2006), P is the concentration of hepatocytes in the incubation mixture, and fu $_{hep}$ is the fraction unbound in hepatocyte incubation calculated based on Log *D* values (Kilford et al., 2008). Log *D* values were predicted using ACD/Laboratories software (Advanced Chemistry Development, Toronto, ON, Canada).

The calculation $f_{m,}$ was obtained as described (eq. 3):

$$f_m = \frac{CL_{int,\ no\ inhibitor} - CL_{int,\ with\ inhibitor}}{CL_{int,\ no\ inhibitor} - CL_{int,\ stromal}} \quad (3)$$

where $CL_{int,\ no\ inhibitor}$ represents the intrinsic clearance value obtained in the absence of inhibitor, $CL_{int,\ with\ inhibitor}$ represents the intrinsic clearance value obtained in the presence of the inhibited data set, and $CL_{int,\ stromal}$ is the intrinsic clearance value obtained from stromal cells, with the assumption that the stromal cells behave in the same manner with or without inhibitor.

Results

Chemical inhibition studies with P450 inhibitors FUR, TA, BNZ, PXT, AZM, and ABT/TA were conducted to assess their selectivity against five P450 enzymes (CYP1A2, 2C9, 2C19, 2D6, and 3A) and broad spectrum inhibition of P450s using 10-donor human hepatocyte pool with HEPATOPAC. The scheme for the chemical inhibition method for low-turnover compounds is depicted in Fig. 1. Initial studies were conducted to demonstrate that P450 activity was maintained for 7 days using P450 probe substrates incubated with human HEPATOPAC (Fig. 2, Table 1). We selected five P450 substrates because each has long been recognized as P450 member-specific reactions (Table 1). P450 activities for CYP2C9, 2C19, 2D6, and 3A maintained approximately ≥80% activity throughout the 7 days of culture. CYP1A2 activities in the absence of inhibitor decreased with time and will require further investigation to ensure that their enzyme activity is maintained over 7 days and complete inhibition observed with time.

The potency and selectivity of P450 chemical inhibitors are displayed in Fig. 3. The data shown that the five P450 chemical inhibitors: FUR, TA, BNZ, PRX, and AZM had good potency and selectivity for their respective P450-isoform. In the current study, FUR (1 μM) exhibited potent inhibitory effect toward the targeted isoform CYP1A2 (~70% inhibition) and good selectivity (<20% inhibition of other P450 activities) within the first day of HEPATOPAC incubation, similar to the results obtained from HLM and hepatocyte suspensions (Newton et al., 1995; Yang et al., 2016). Evaluation of native CYP1A2 activity revealed a time-dependent loss of enzyme activity (Fig. 3) that mirrored the reduction in inhibitory potency of FUR. TA reduced ~80% of CYP2C9 activity with good selectivity over the 7-day incubation period (Fig. 3). BNZ reduced ~80% of CYP2C19 activity with good selectivity over the 7-day incubation period (Suzuki et al., 2002) (Fig. 3). An increase of CYP3A activity up to 2-fold by day 7 was detected after a daily administration of BNZ. PXT exhibited an average of ~80% inhibition of CYP2D6 activity over 7 days when the compound was applied three times over the course of the experiment at pretreatment, day 1, and day 4. Although the selectivity profile toward P450s 1A2 and 2C9 appeared to be greater than 80%, considerable inhibition (~50%) of CYP2C19 activity by PXT was also observed (Fig. 3), a phenomenon that was previously reported (Kobayashi et al., 1995). CYP3A activity appeared to be ~80% for days 0–4 and P450 3A activity declines to ~60% for days 5–7. Utilization of AZM in human HEPATOPAC resulted in persistent reduction (≥80%) in CYP3A activity and good selectivity (<20% inhibition of other P450 activities) over a 7-day incubation period (Fig. 3). Using global inhibition of P450s with the relatively nonselective inhibitor ABT and TA to inhibit CYP2C9 effectively demonstrated that ~95% activity was lost for the five P450s, and sustained inhibition of P450 activity was possible with daily addition of these inhibitors (Fig. 4).



Fig. 2. Representative P450 activity over the 7-day human hepatocyte pool with HEPATOPAC incubation period. Each data point represents average ± S.E. from n = 4–8 experiments, each obtained from triplicates determinations, for CYP1A2 (★), CYP2C9 (■), CYP2C19 (△), CYP2D6 (◆), or CYP3A (◯).

The inhibitory effects of the selective inhibitors were also evaluated with several low-turnover compounds using human HEPATOPAC (Fig. 5). The intrinsic clearance and the respective f_m values for the low-turnover compounds in the presence and absence of the chemical inhibitors are shown in Table 2. Utilization of FUR for CRP was evaluated with tizanidine, a compound predominantly metabolized by CYP1A2 (Granfors et al., 2004). Treatment with FUR reduced clearance of tizanidine by 91% (Fig. 5, Table 2) and is comparable to the value previously obtained with human liver microsomes (Gransfors et al., 2004). TA greatly reduced CYP2C9-mediated tolbutamide clearance in human HEPATOPAC with an estimated f_m value of 1.0 for CYP2C9 (Fig. 5; Table 2), which is consistent with the reported values ranging from 0.8 to 1 (Veronese et al., 1991; Yang et al., 2016). Treatment with BNZ reduced voriconazole CL_{int} by 40%, which is also in line with previously published data showing CYP2C19 contributed to ~35% of the formation of the major *N*-oxide metabolite (Fig. 5) (Yanni et al., 2010). A CPR study was conducted with risperidone, a compound predominantly metabolized by CYP2D6 (Berecz et al., 2004), and the f_m was estimated to be 0.83 (Fig. 5; Table 2), which is consistent with previously reported in vitro f_m values. Applicability of AZM for CRP in human HEPATOPAC was validated with disopyramide, a compound metabolized predominantly by CYP3A (Echizen et al., 2000; Ma et al., 2017). CYP3A was found to be contributing to the total disopyramide clearance in the current assay (Fig. 5; Table 2), consistent with results reported in the literature (Echizen et al., 2000).

TABLE 1

Selective substrates and corresponding metabolites for P450 isoforms

Substrate (concentration)	P450 isoform	Metabolite
Phenacetin (100 μM)	1A2	Acetaminophen
Diclofenac (25 μM)	2C9	4'-Hydroxdiclofenac
S-Mephenytoin (150 μM)	2C19	4'-Hydroxymephenytoin
Dextromethorphan (25 μM)	2D6	Dextrorphan
Midazolam (15 μM)	3A	1'-Hydroxymidazolam



Fig. 3. P450 inhibitor (FUR, TA, BNZ, PXT, AZM) selectivity in HEPATOPAC 10-donor human hepatocyte pool with HEPATOPAC measuring P450 activity remaining over 7 days. Percent activity of the P450s as function of time was shown as mean ± S.D. from triplicate, determinations were plotted for CYP1A2 (★), CYP2C9 (■), CYP2C19 (△), CYP2D6 (◆), or CYP3A (◯) .



Fig. 4. Pan-cytochrome inhibitor ABT/TA in HEPATOPAC 10-donor human hepatocyte pool measuring P450 activity remaining over 7 days. Percent activity of the P450s as function of time was shown as mean ± S.D. from triplicate, determinations were plotted for CYP1A2 (★), CYP2C9 (■), CYP2C19 (△), CYP2D6 (◆), or CYP3A (◯).

Discussion

Determination of f_m via CRP studies is an important aspect in assessing DDI liabilities of NCEs (Zhang et al., 2007; Zientek and Youdim, 2015; Ogilive et al., 2019). Typical CRP approaches rely on a combination of inhibition of activity with human liver microsomes, using either specific chemical inhibitors or inhibitory antibodies, complemented with metabolism by individual recombinant P450 isoforms. With enzyme activities of these cell-free preparations deteriorating substantially in a matter of hours, the applicability of traditional CRP approaches to low-turnover compounds is limited. Hence, development of a CRP method in hepatocyte cocultures provides an opportunity to evaluate DDI liabilities for low-turnover NCEs.

Recent development of long-term human hepatocyte cocultures showed promising results in predictions of metabolic clearance (Chan et al., 2013; Kratochwil et al., 2017; Gibson et al., 2021). For human HEPATOPAC, the accuracy of prediction (defined as within 3-fold of the observed in vivo clearance) ranged from 82% to 92% across laboratories, and the tendency for underprediction or interindividual variability was lower than those obtained from hepatocyte suspensions or plated hepatocytes (Gibson et al., 2021). In the current study, the ability to selectively inhibit P450 activities with chemical inhibitors in human HEPATOPAC has been demonstrated for an incubation period of up to 7 days. Overall, chemical inhibitors used in the current method demonstrated reasonably good selectivity profiles in human HEPATOPAC, as supported by consistent results obtained from confirmatory f_m determinations (Fig. 4; Table 2). It is anticipated that the current method is also applicable to other human hepatocyte coculture models.

One key aspect of establishing a CRP method is the demonstration of selective inhibition. For a cell-based hepatocyte system where a whole host of DME are functional, the prospect of a narrowing selectivity window over time as a result of nonselective inhibitory effects exhibited by metabolite(s) of the inhibitor is of particular concern. To circumvent this challenge, time-dependent inhibitors were readily used in hepatocyte-based CRP (Yang et al., 2016; Chanteux et al., 2020). This approach is also applied to the current method with human HEPATOPAC, achieving sustained selectivity for up to 7 days of incubation. It is also important to note that potent reversible inhibitors exhibiting an appreciative selectivity profile are useful in hepatocyte-based CRP



Fig. 5. Inhibition profiles of P450 reaction phenotyping using novel HEPATOPAC method for low-turnover compounds. All assays and measurements were performed in triplicate determinations. Parent disappearance versus time profiles of low-turnover substrates were generated for untreated (○) and treated with chemical inhibitor (●) or incubated with mouse embryonic 3T3 fibroblasts (stromal cells) (▲).

(Yang et al., 2016). In human HEPATOPAC, BNZ displayed selective inhibition toward CYP2C19 (Fig. 3A). Of note, the usage of omeprazole, a mechanism-based inhibitor of CYP2C19 (Shirasaka et al., 2013), did not replicate the selective inhibitory effect achieved at 8 μM in human hepatocyte suspensions (Yang et al., 2016) with only ∼50% reduction in CYP2C19 activity obtained in human HEPATOPAC (data not shown). For inhibitors used in the current P450 method, further characterization of the selectivity profile toward other DME will be important when using hepatocytes such as HEPATOPAC. Although inactivators of other important P450 isoforms have been recognized, e.g., clopidogrel for CYP2B6 and gemfibrozil glucuronide for CYP2C8 (Mohutsky and Hall, 2021), these were not evaluated in the current study. Since mechanism-based inhibitors require metabolic activation, this mechanism will not occur with many other DME and, as such, it was important that we were also able to demonstrate extended inhibition using a competitive inhibitor (i.e., BNZ).

FUR (1 μM) exhibited potent inhibitory effect toward the targeted isoform CYP1A2 (∼70% inhibition) and good selectivity (<20% inhibition on other P450 activities) within the first day of HEPATOPAC incubation, similar to the results obtained from human liver microsomes and hepatocyte suspensions (Newton et al., 1995; Yang et al., 2016). Surprisingly, a gradual decline of inhibitory effect on CYP1A2 enzyme activity in HEPATOPAC was observed, with minimal/no inhibition detected beyond three days of incubation (Fig. 2). Evaluation of native CYP1A2 activity revealed a time-dependent loss of enzyme activity (Fig. 3) that mirrored the reduction in inhibitory potency of FUR. In a previous study, CYP1A2 activity in human HEPATOPAC was monitored on days 7, 9, 15, 19, 25, and 30 (Lin and Khetani, 2017), and the observed CYP1A2 activities were reasonably variable (∼4-fold difference between the minimum and maximum values with no apparent trend) across time points. It is possible that the trend of declining CYP1A2 activity was not captured (Lin and Khetani, 2017). To date, the underlying mechanism for the observed reduction in CYP1A2 activity in human HEPATOPAC is not known.

Constant P450 activities over the incubation period is a prerequisite to evaluate the selectivity and potency of chemical inhibitors and enables scientists to determine the fraction by which a specific P450 isoform is involved in the metabolic clearance of compounds. Throughout the course of a 7-day incubation period, an increase in distinct enzyme activities was observed with TA, AZM, and BNZ, but not with the other reported chemical inhibitors. AZM and TA increased CYP3A4 mRNA by 22.2-fold and 8.2-fold in cultured hepatocytes, respectively, and are in vitro inducers (Supplemental Table 1). Incubating HEPATOPAC with TA for 7 days showed a potent and selective inhibition of CYP2C9 and a 5-fold increase in CYP3A4 activity. A lower TA concentration of 0.015 μM decoupled the inhibition and induction effect and resulted in a potent and selective CYP2C9 inhibition while maintaining constant CYP3A activity.

Despite showing a concentration-dependent increase in CYP3A4 mRNA, AZM demonstrated potent inhibition of CYP3A enzyme activity in HEPATOPAC. At the same time, AZM increased the CYP2D6 activity by less than 2-fold when incubated in HEPATOPAC for 7 days at 1 μM. This was an unusual observation, as CYP2D6 is believed to be not inducible in vitro (Ingelman-Sundberg, 2005). A plausible explanation for this observation could be protein-protein interactions, which have been described in the literature to modulate P450 activity including CYP2D6 (Yamazaki et al., 1994; Subramanian et al., 2009; Subramanian et al., 2010; Ramsden et al., 2014; Reed and Backes, 2016). Incubations with BNZ lead to a 2-fold increase in CYP3A activity (Fig. 3), suggesting that this close analog of phenobarbital, a known inducer of CYP3A4 expression in vitro (Rhodes et al., 2011), may also be an

TABLE 2

Fraction of metabolism determination in human HEPATOPAC

Low-turnover compound	In vitro Inhibitor (Concentration)	Observed in vitro CL_{int} (ml/min/kg) without inhibitor	with inhibitor	f_m observed	f_m reported (P450 isoform)	Human Hepatocyte Lot [number of donor(s)]
Tizanidine	Furafylline (1.0 μM)	24	2.0	0.91	0.85 (P450 1A2)[a]	VKB (single-donor)
Tolbutamide	Tienilic acid (0.015 μM)	1.8	ND	1.0	0.80 to 1.0 (CYP2C9)[b]	KCB (10 donors)
Voriconazole	(+)-*N*-3-benzyl-nirvanol (0.5 μM)	11	6.7	0.40	0.35 (CYP2C19)[c]	KCB (10 donors)
Risperidone	Paroxetine (1.8 μM)	24	4.0	0.83	Mostly (CYP2D6)[d]	AMH (10 donors)
Disopyramide	Azamulin (1.0 μM)	12	0.10	0.99	Mostly (CYP3A)[e]	AMH (10 donors)

ND, No depletion was observed.
[a] Gransfors et al., 2004
[b] Miller et al., 1990
[c] Yanni et al., 2010
[d] Berecz et al., 2004
[e] Echizen et al., 2002

inducer in vitro. Further evidence was observed as the CL_{int} for disopyramide, prototypic substrate of CYP3A, was increased by 2-fold after treatment with BNZ (Supplemental Figure 1).

A CRP method useful for low-turnover compounds has been established using HEPATOPAC, and the applicability has been verified with confirmatory f_m determination using low clearance compounds. As a proof-of-principle study, this method offers a generic approach for CRP studies to be conducted in other hepatocyte coculture models. This assay generates quantitative CRP data, which can be used to identify victim DDI risks of low-turnover NCEs prior to first in human studies and helps for planning of clinical DDI studies.

Acknowledgments

The authors would like to thank Jeannemarie Gaffney from Ascendance/BioIVT for supplying HEPATOPAC plates and Deborah Newton from Merck & Co., Inc., Kenilworth, NJ, for assisting with P450 induction screening.

Authorship Contributions

Participated in research design: Smith, Lyman, Ma, Menzel.

Conducted experiments: Smith, Lyman.

Performed data analysis: Smith, Ma.

Wrote or contributed to the writing of the manuscript: Smith, Lyman, Ma, Tweedie, Menzel.

References

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. *Curr Drug Metab* **8**:33–45.

Berecz R, Dorado P, De La Rubia A, Cáceres MC, Degrell I, and LLerena A (2004) The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. *Curr Drug Targets* **5**:573–579.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al.; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER) (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. *Drug Metab Dispos* **31**:815–832.

Bleecker ER, Bateman ED, Busse WW, Woodcock A, Frith L, House KW, Jacques L, Davis AM, Haumann B, and Lötvall J (2012) Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. *Ann Allergy Asthma Immunol* **109**:353–358.e4.

Bonn B, Svanberg P, Janefeldt A, Hultman Ia, and Grime K (2016) Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary hepatocytes and HepaRG. *Drug Metab Dispos* **44**:527–533.

Cerny MA (2016) Prevalence of non-cytochrome P450-mediated metabolism in Food and Drug Administration-approved oral and intravenous drugs: 2006-2015. *Drug Metab Dispos* **44**:1246–1252.

Chan TS, Yu H, Moore A, Khetani SR, and Tweedie D (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. *Drug Metab Dispos* **41**:2024–2032.

Chanteux H, Rosa M, Delatour C, Nicolaï J, Gillent E, Dell'Aiera S, and Ungell A-L (2020) Application of azamulin to determine the contribution of CYP3A4/5 to drug metabolic clearance using human hepatocytes. *Drug Metab Dispos* **48**:778–787.

Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford AC, Tan B, McDonald TS, Lai Y, and Tremaine LM (2012) A novel relay method for determining low-clearance values. *Drug Metab Dispos* **40**:1860–1865.

Di L (2017) Reaction phenotyping to assess victim drug-drug interaction risks. *Expert Opin Drug Discov* **12**:1105–1115.

Elaut G, Papeleu P, Vinken M, Henkens T, Snykers S, Vanhaecke T, and Rogiers V (2006) Hepatocytes in suspension. *Methods Mol Biol* **320**:255–263.

Echizen H, Tanizaki M, Tatsuno J, Chiba K, Berwick T, Tani M, Gonzalez FJ, and Ishizaki T (2000) Identification of CYP3A4 as the enzyme involved in the mono-*N*-dealkylation of disopyramide enantiomers in humans. *Drug Metab Dispos* **28**:937–944.

Fujino T, Park SS, West D, and Gelboin HV (1982) Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies. *Proc Natl Acad Sci USA* **79**:3682–3686.

Gibson CR, Wang Y-H, Varkhede N, and Ma B (2021) Variability in human in vitro enzyme kinetics in *Enzyme kinetics in drug metabolism: Fundamentals and applications.* 2nd ed. (Nagar S., Argikar UA, and Tweedie DJ, Eds) Springer 443–479.

Gransfors MT, Backman JT, Laitila J, and Neuvonen PJ (2004) Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. *Br J Clin Pharmacol* **57**:349–353.

Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. *Xenobiotica* **36**:473–497.

Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J* **5**:6–13.

Kilford PJ, Gertz M, Houston JB, and Galetin A (2008) Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. *Drug Metab Dispos* **36**:1194–1197.

Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. *Nat Biotechnol* **26**:120–126.

Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, and Kuroiwa Y (1995) The effects of selective serotonin reuptake inhibitors and their metabolites on *S*-mephenytoin 4′-hydroxylase activity in human liver microsomes. *Br J Clin Pharmacol* **40**:481–485.

Kratochwil NA, Meille C, Fowler S, Klammers F, Ekiciler A, Molitor B, Simon S, Walter I, McGinnis C, Walther J, et al. (2017) Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling. *AAPS J* **19**:534–550.

Lin C and Khetani SR (2017) Micropatterned co-cultures of human hepatocytes and stromal cells for the assessment of drug clearance and drug-drug interactions. *Curr Protocols Toxicol* **72**:14.17.1–14.17.23.

Ma B, Eisenhandler R, Kuo Y, Rearden P, Li Y, Manley PJ, Smith S, and Menzel K (2017) Prediction of metabolic clearance for low-turnover compounds using plated hepatocytes with enzyme activity correction. *Eur J Drug Metab Pharmacokinet* **42**:319–326.

Miller AK, Adir J, and Vestal RE (1990) Excretion of tolbutamide metabolites in young and old subjects. *Eur J Clin Pharmacol* **38**:523–524.

Mohutsky M and Hall SD (2021) Irreversible enzyme inhibition kinetics and drug-drug interactions, in *Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications*, Ed. 2nd (Nagar S, Argikar UA, and Tweedie DJ, eds) pp 51–88, New York: Springer.

Newton DJ, Wang RW, and Lu AYH (1995) Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. *Drug Metab Dispos* **23**:154–158.

Ogilive BW, Usuki E, Yerino P, and Parkinson A (2019) In vitro approaches for studying the inhibition of drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. *Drug-Drug Interactions*, 2nd edition. (Rodriquez D A, ed) CRC press pp 231–346.

Ramsden D, Tweedie DJ, Chan TS, and Tracy TS (2014) Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions. *Drug Metab Dispos* **42**:1940–1946.

Reed JR and Backes WL (2016) The functional effects of physical interactions involving cytochromes P450: putative mechanisms of action and the extent of these effects in biological membranes. *Drug Metab Rev* **48**:453–469.

Rhodes SP, Otten JN, Hingorani GP, Hartley DP, and Franklin RB (2011) Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2. *J Pharmacol Toxicol Methods* **63**:223–226.

Shirasaka Y, Sager JE, Lutz JD, Davis C, and Isoherranen N (2013) Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. *Drug Metab Dispos* **41**:1414–1424.

Smith DA, Beaumont K, Maurer TS, and Di L (2018) Relevance of half-life in drug design. *J Med Chem* **61**:4273–4282.

Stringer R, Nicklin PL, and Houston JB (2008) Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. *Xenobiotica* **38**:1313–1329.

Subramanian M, Low M, Locuson CW, and Tracy TS (2009) CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. *Drug Metab Dispos* **37**:1682–1689.

Subramanian M, Tam H, Zheng H, and Tracy TS (2010) CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. *Drug Metab Dispos* **38**:1003–1009.

Suzuki H, Kneller MB, Haining RL, Trager WF, and Rettie AE (2002) (+)-*N*-3-Benzyl-nirvanol and (-)-*N*-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. *Drug Metab Dispos* **30**:235–239.

Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, and Birkett DJ (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. *Biochem Biophys Res Commun* **175**:1112–1118.

Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, and Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. *Mol Pharmacol* **46**:568–577.

Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. *Curr Drug Metab* **9**:384–394.

Yang X, Atkinson K, and Di L (2016) Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method. *Drug Metab Dispos* **44**:460–465.

Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin Jr DK, and Thakker DR (2010) In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. *Drug Metab Dispos* **38**:25–31.

Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. *Expert Opin Drug Metab Toxicol* **3**:667–687.

Zientek MA and Youdim K (2015) Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. *Drug Metab Dispos* **43**:163–181.

Address correspondence to: Sheri Smith, Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, WP75A-200, Merck & Co., Inc., West Point, PA 19486. E-mail: sheri_smith3@merck.com

Reaction Phenotyping of Low-Turnover Compounds in Long-term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450

Sheri Smith, Michael Lyman, Bennett Ma, Donald Tweedie and Karsten Menzel

Drug Metabolism and Disposition

DMD-AR-2021-000601

Table S1: CYP3A4 Induction by AZM and TA

The Effect of Selected Test Articles on CYP3A4 mRNA in Cryopreserved Human Hepatocytes (Lot 336)

Treatment	[µM]	hCYP3A4 mRNA	
		Fold[a]	% of PC[b]
RIF	10	28.4	100.0
Azamulin	0.1	1.4	1.5
	0.5	2.9	6.8
	1	4.5	12.6
	5	14.5	49.4
	10	19.6	68.0
	20	22.2	77.3
Tienilic Acid	0.1	1.0	0.1
	0.5	1.1	0.5
	1	1.4	1.3
	5	2.8	6.4
	10	4.7	13.5
	20	8.2	26.3

Figure S1: Disopyramide in the presence and absence of BNZ (CYP3A)



Table S2 Analyte/Internal Standard Pairing

Analyte	**Internal Standard**
Acetominophen	Labetalol/Imipramine
4'-OH-diclofenac	Labetalol/Imipramine
4'-OH-mephenytoin	Labetalol/Imipramine
Dextrorphan	Labetalol/Imipramine
1'-OH-Midazolam	Labetalol/Imipramine
Tizanidine	Labetalol
Tolbutamide	Labetalol/Imipramine
Voriconazole	Labetalol
Risperidone	Labetalol

Disopyramide	Labetalol